Skip to search formSkip to main contentSkip to account menu

Fumagillin-Derived Polymer Conjugate XMT-1107

Known as: XMT-1107 
A polymeric prodrug consisting of the fumagillol-derived small molecule XMT-1191 tethered to the hydrophilic, biodegradable70 kDa polymer poly[1… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors.
2526 Background: Fumagillol derivatives are novel anti-angiogenic agents that inhibit methionine aminopeptidase 2 (MetAP2) rather… 
2010
2010
Mersana and Teva in USD 334 M deal for preclinical cancer drug
Teva Pharmaceutical Industries has entered into an agreement with Mersana Therapeutics for rights to develop and commercialize… 
2010
2010
Abstract 2664: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat and the dog
XMT-1107 is a novel polymer fumagillol derivative, comprised of the small molecule XMT-1191 conjugated to a 70 kDa biodegradable… 
2009
2009
Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat
XMT-1107 is a novel polymer fumagillol derivative, comprised of the small molecule XMT-1191 conjugated to a 70 kDa biodegradable… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)